CTOR
Citius Oncology, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Citius Oncology, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Oncology, Inc. is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Oncology, Inc. is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc.
Annual filing, covered
10-K parsed · Dec 23 '25
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Dec 23 '25
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Citius Oncology, Inc.
0.57
−0.02 · −3.30%
post 0.55 −3.64%
0.00%
CTOR weight · VTI
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Citius Oncology, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Citius Oncology, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| Armistice Capital | $5.7M | 61.55% | −5.26% |
| Bank of America | $2.5M | 27.11% | 0.00% |
| Vanguardindex-like | $355,111 | 3.86% | +2.15% |
| UBS | $217,502 | 2.37% | +808.30% |
| Geodeindex-like | $159,538 | 1.74% | −7.30% |
| Manager | Value | % base | |
|---|---|---|---|
| Armistice Capital | $5.7M | 61.55% | −5.26% |
| Bank of America | $2.5M | 27.11% | 0.00% |
| Vanguardindex-like | $355,111 | 3.86% | +2.15% |
| UBS | $217,502 | 2.37% | +808.30% |
| Geodeindex-like | $159,538 | 1.74% | −7.30% |
−1.36%
shares held · 10 largest managers
Bull1
Bear1
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.